T2334

Avanafil (TA1790) is a selective inhibitor of phosphodiesterase type 5 (PDE5) and is used as therapy of erectile dysfunction.

SDZ 220-040 is a selective mammalian NMDA receptor antagonist that induces a partially gravity-free mode of root growth.

SDZ 220-040 ammonium is a competitive glutamate ionotropic receptor NMDA antagonist used in the study of neurological disorders.

SF 11 is a potent, brain-penetrant neuropeptide Y Y2 receptor antagonist with an IC50 of 199 nM, exhibiting antidepressant-like activity.

SD 1008 is a JAK2/STAT3 signaling pathway inhibitor. SD 1008 inhibits activation of STAT3, JAK2, and Src.

SDZ 205-557 hydrochloride is a selective 5-HT4 receptor antagonist that effectively blocks serotonin-mediated signaling, SDZ 205-557 hydrochloride is widely applied in neurological and gastrointestinal research to study 5-HT4 receptor function, neurotransmission modulation, cognitive processes, and receptor-specific pharmacology in both in vitro and in vivo experimental systems.

β-adrenoceptor and 5-HT1A/1B receptor antagonist

human tachykinin NK1 receptor antagonist

SDZ WAG 994 is an A1 adenosine receptor agonist.

SEN12333 is an α7 nicotinic acetylcholine receptor (nAChR) agonist

Avanafil-13C-D3 the 13C and deuterated compound of Avanafil (T2334). Avanafil has a CAS number of 330784-47-9. Avanafil is a selective inhibitor of phosphodiesterase type 5 (PDE5) and is used as therapy of erectile dysfunction.